Editorial

SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now

Jonathan J. Taliercio, DO, George Thomas, MD, Georges N. Nakhoul, MD, MEd, Tushar J. Vachharajani, MD and Ali Mehdi, MD, MEd
Cleveland Clinic Journal of Medicine January 2021, 88 (1) 59-63; DOI: https://doi.org/10.3949/ccjm.88a.20190

Article Information

vol. 88 no. 1 59-63
DOI 
https://doi.org/10.3949/ccjm.88a.20190
PubMed 
33384316
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online December 31, 2020.
Copyright & Usage 
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Jonathan J. Taliercio, DO⇑
  1. Program Director, Nephrology and Hypertension Fellowship, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study
  1. Address:
    Jonathan J. Taliercio, DO, Department of Nephrology and Hypertension, Q7, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; talierj{at}ccf.org
  1. George Thomas, MD
  1. Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study
  1. Georges N. Nakhoul, MD, MEd
  1. Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Co-investigator, EMPA-KIDNEY study
  1. Tushar J. Vachharajani, MD
  1. Department of Hypertension and Nephrology, Glickman Urological and Kidney Institute, Cleveland Clinic; Clinical Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Principal Investigator, EMPA-KIDNEY study
  1. Ali Mehdi, MD, MEd
  1. Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects